Drug search by name

Gadopentetate Injection and Renal impairment

Result of checking the interaction of drug Gadopentetate Injection and disease Renal impairment for safety when used together.

Check result:

Gadopentetate Injection <> Renal impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury. GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes). Always estimate the glomerular filtration rate (GFR) through laboratory testing.

Gadopentetate Injection

Generic Name: gadopentetate dimeglumine

Brand Name: Magnevist, Multihance

Synonyms: Gadopentetate dimeglumine

What is Gadopentetate Injection?